Traws Pharma Stock Price To Earning

TRAW Stock   5.02  0.31  5.82%   
Traws Pharma fundamentals help investors to digest information that contributes to Traws Pharma's financial success or failures. It also enables traders to predict the movement of Traws Stock. The fundamental analysis module provides a way to measure Traws Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Traws Pharma stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Traws Pharma Company Price To Earning Analysis

Traws Pharma's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

P/E

 = 

Market Value Per Share

Earnings Per Share

More About Price To Earning | All Equity Analysis

Traws Price To Earning Driver Correlations

Understanding the fundamental principles of building solid financial models for Traws Pharma is extremely important. It helps to project a fair market value of Traws Stock properly, considering its historical fundamentals such as Price To Earning. Since Traws Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Traws Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Traws Pharma's interrelated accounts and indicators.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Competition

Traws Retained Earnings

Retained Earnings

(506.76 Million)

Traws Pharma reported Retained Earnings of (482.63 Million) in 2023
Based on the latest financial disclosure, Traws Pharma has a Price To Earning of 0.0 times. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the Health Care industry. The price to earning for all United States stocks is 100.0% higher than that of the company.

Traws Price To Earning Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Traws Pharma's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Traws Pharma could also be used in its relative valuation, which is a method of valuing Traws Pharma by comparing valuation metrics of similar companies.
Traws Pharma is currently under evaluation in price to earning category among its peers.

Traws Pharma Current Valuation Drivers

We derive many important indicators used in calculating different scores of Traws Pharma from analyzing Traws Pharma's financial statements. These drivers represent accounts that assess Traws Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Traws Pharma's important valuation drivers and their relationship over time.
201920202021202220232024 (projected)
Market Cap136.7M2.0B1.1B339.8M414.5M434.3M
Enterprise Value113.9M2.0B1.0B301.0M393.7M412.8M

Traws Fundamentals

About Traws Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Traws Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Traws Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Traws Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Traws Stock Analysis

When running Traws Pharma's price analysis, check to measure Traws Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Traws Pharma is operating at the current time. Most of Traws Pharma's value examination focuses on studying past and present price action to predict the probability of Traws Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Traws Pharma's price. Additionally, you may evaluate how the addition of Traws Pharma to your portfolios can decrease your overall portfolio volatility.